US FDA approves GSK's Cervarix for prevention of HPV 16/18 cervical disease
This article was originally published in Scrip
The US FDA on October 16th approved GlaxoSmithKline's vaccine Cervarix for prevention of cervical cancer and pre-cancerous lesions caused by human papillomavirus types 16 and 18 in women aged 10-25 years.
You may also be interested in...
La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher; Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.